News

Specific nerve cells are critically involved in the development of epileptic seizures, hyperactivity, autistic-like behaviors, and cognitive declines in Dravet syndrome, according to a mouse study from Japan. The research, “Impairments in social novelty recognition and spatial memory in mice with conditional deletion of Scn1a in parvalbumin-expressing…

Perampanel, as an add-on therapy, efficiently reduced seizure rates in children with Dravet syndrome, a real-world study shows. The study, “Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics,” was published in the journal Epilepsy &…

The ketogenic diet, which is high in fats and low in carbs, helped reduce the frequency of seizures and improve cognitive function in children with Dravet syndrome who are resistant to standard therapies, a small study in China found. The study, “Prospective study of the efficacy of a ketogenic…

Zogenix reported positive top-line results from a second confirmatory Phase 3 study investigating the use of ZX008 (low-dose fenfluramine hydrochloride) in treating children and young adults with Dravet syndrome, and said that it plans to request regulatory approval. The Phase 3 trial (NCT02926898) — also known as study…

Add-on therapy with Fycompa (perampanel) is safe and effective in preventing seizures in adolescents with treatment-resistant refractory epilepsy, according to a real-world retrospective study from Taiwan. The study, “Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian…

A new mutation associated with Dravet syndrome was identified in an Iranian family with suspected disease, according to case report. The study, “Pathogenic significance of SCN1A splicing variants causing Dravet syndrome: improving diagnosis with targeted sequencing for variants by in silico analysis,” was published in Clinical Neurology and Neurosurgery.

A phenomenon known as “genetic mosaicism” may contribute to milder symptoms in people with Dravet syndrome and related disorders, a new study shows. The study, “Mosaicism of de novo pathogenic SCN1A variants in epilepsy is a frequent phenomenon that correlates with variable phenotypes,” was published in the journal…

ZX008, an experimental therapy for Dravet syndrome, was found to be well-tolerated and can be administered regardless of food intake, according to clinical results of a study in healthy volunteers. The findings mean that ZX008 likely will be easier to…

Dravet patients have an abnormal inflammatory reaction to vaccines, supporting a potential link between inflammation and epileptic seizures in these patients, according to a small study. The study, “Altered vaccine-induced immunity in children with Dravet syndrome,” was published in the journal Epilepsia. Dravet syndrome is a…

The U.S. Food and Drug Administration has approved Epidiolex to treat Dravet and Lennox-Gastaut syndromes, making history as the first therapy approved to treat Dravet, as well as the first marijuana-derived treatment to receive FDA approval for any indication. GW Pharmaceutical‘s plant-derived cannabinoid medicine was approved to…